- Home
- TPST vs SNTI Comparison
TPST vs SNTI Comparison
Compare TPST & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- SNTI
- Stock Information
- Founded
- TPST 2011
- SNTI 2016
- Country
- TPST United States
- SNTI United States
- Employees
- TPST N/A
- SNTI N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- SNTI Health Care
- Exchange
- TPST Nasdaq
- SNTI Nasdaq
- Market Cap
- TPST 45.5M
- SNTI 39.6M
- IPO Year
- TPST N/A
- SNTI N/A
- Fundamental
- Price
- TPST $9.58
- SNTI $1.37
- Analyst Decision
- TPST Hold
- SNTI Strong Buy
- Analyst Count
- TPST 3
- SNTI 2
- Target Price
- TPST $30.00
- SNTI $8.50
- AVG Volume (30 Days)
- TPST 54.6K
- SNTI 120.0K
- Earning Date
- TPST 11-11-2025
- SNTI 11-13-2025
- Dividend Yield
- TPST N/A
- SNTI N/A
- EPS Growth
- TPST N/A
- SNTI N/A
- EPS
- TPST N/A
- SNTI N/A
- Revenue
- TPST N/A
- SNTI N/A
- Revenue This Year
- TPST N/A
- SNTI N/A
- Revenue Next Year
- TPST N/A
- SNTI $150.00
- P/E Ratio
- TPST N/A
- SNTI N/A
- Revenue Growth
- TPST N/A
- SNTI N/A
- 52 Week Low
- TPST $5.35
- SNTI $1.26
- 52 Week High
- TPST $20.67
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- TPST 47.99
- SNTI 37.01
- Support Level
- TPST $9.90
- SNTI $1.33
- Resistance Level
- TPST $11.02
- SNTI $1.39
- Average True Range (ATR)
- TPST 0.62
- SNTI 0.08
- MACD
- TPST -0.20
- SNTI 0.01
- Stochastic Oscillator
- TPST 4.78
- SNTI 31.43
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.